Rankings
▼
Calendar
INDV FY 2025 Earnings — Indivior Pharmaceuticals Inc Revenue & Financial Results | Market Cap Arena
INDV
Indivior Pharmaceuticals Inc
$4B
FY 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$1.2B
+4.3% YoY
Gross Profit
$994M
80.2% margin
Operating Income
$262M
21.1% margin
Net Income
$210M
16.9% margin
EPS (Diluted)
$1.64
Cash Flow
Operating Cash Flow
-$27M
Free Cash Flow
-$93M
Stock-Based Comp.
$26M
Balance Sheet
Total Assets
$1.2B
Total Liabilities
$1.3B
Stockholders' Equity
-$98M
Cash & Equivalents
$195M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$1.2B
$1.2B
+4.3%
Gross Profit
$994M
$957M
+3.9%
Operating Income
$262M
$32M
+718.8%
Net Income
$210M
$2M
+10400.0%
← Q4 2024
All Quarters
Q1 2025 →